Metrics as of 10/13/2026, 06:34 PM (Berlin time), refresh in progress.
Kiora Pharmaceuticals Stock
Kiora Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Brian Strem
- Employees
- 13
- Market cap
- $11 M
- IPO
- 13/02/2015
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1…
Kiora Pharmaceuticals stock: price history
1D
-1.4%
1W
+1.0%
1M
-4.7%
6M
+3.5%
YTD
+28.2%
1Y
-7.2%
2Y
-26.6%
5Y
-99.6%
10Y
-100.0%
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~37% weaker price swings than usual
Ask the agents about Kiora Pharmaceuticals
Analyst assessment of Kiora Pharmaceuticals
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 02/09/2025
Kiora Pharmaceuticals stock metrics
P/E
-1.01
P/B
0.93
EV/EBITDA
-0.36
RETURN ON EQUITY
-12.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.2%
FLOAT SHARES
4,174,648
AVG. DAILY VOLUME (30D)
13,198
Insider transactions (SEC)
Strem Brian M.
Tosca Melissa
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Kiora Pharmaceuticals stock
What does Kiora Pharmaceuticals do?
Kiora Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Brian Strem, the company employs around 13 people.
The IPO was on 13/02/2015; the stock trades on NASDAQ under the ticker KPRX.
What do analysts say about Kiora Pharmaceuticals stock?
3 analysts rate the stock, the consensus is Buy (as of 02/09/2025).
This is an external assessment, not a statement by Market Jury.
When does Kiora Pharmaceuticals report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly -37% stronger than usual.
Does Kiora Pharmaceuticals pay a dividend?
No, Kiora Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Kiora Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kiora Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kiora Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.